Status: Not yet recruiting
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors
This study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.
Participants needed: 486
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Rongchang Pharmaceuticals Co., Ltd.Updated: Sep 8, 2026Locations: 8
Eligibility criteria
Voluntarily participate in this study, sign the informed consent form, and be ab... [+5]
Female participants who are pregnant, lactating, or planning to become pregnant. [+18]